Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pyogenic bacterial infection due to MyD88 deficiency is a primary immunodeficiency characterized by increased susceptibility to pyogenic bacterial infections, including invasive pneumococcal, invasive staphylococcal and pseudomonas disease.
Features include always present findings: Delayed umbilical cord separation; and common findings: Recurrent meningitis and Abscess. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 1 | Recurrent meningitis |
MYD88 encodes MYD88 innate immune signal transduction adaptor (296 aa). Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response. Highest expression in Whole Blood (199.5 TPM) and Spleen (107.1 TPM).
Pyogenic bacterial infections due to MyD88 deficiency is associated with mutations in the MYD88 gene on chromosome 3.
MYD88 is classified as a druggable target (Cell Surface, Clinically Actionable, and Serine Threonine Kinase categories) with score 4.4.
Genetic testing for MYD88 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 2 common features.
No clinical trials have been registered for pyogenic bacterial infections due to MyD88 deficiency.
16 publications have been identified in PubMed for pyogenic bacterial infections due to MyD88 deficiency. Research spans Basic Science / Preclinical (56%), Case Report / Case Series (25%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 9 | 56% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:48 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Recurrent skin infections |
Blood and immune system | 1 | Recurrent skin infections |
Bones and joints | 1 | Septic arthritis |
Age of onset: at birth.
Patient case studies |
4 |
25% |
Research summaries | 2 | 13% |
Disease patterns and progression | 1 | 6% |
Hanaford AR (2026). [PMID: 42182173](https://pubmed.ncbi.nlm.nih.gov/42182173/). *bioRxiv*. [Basic Science / Preclinical]
Akçay N (2026). [PMID: 41066308](https://pubmed.ncbi.nlm.nih.gov/41066308/). *J Child Neurol*. [Case Report / Case Series]
Si W (2026). [PMID: 41363121](https://pubmed.ncbi.nlm.nih.gov/41363121/). *Immunology*. [Basic Science / Preclinical]
Wild S (2026). [PMID: 41993090](https://pubmed.ncbi.nlm.nih.gov/41993090/). *Eur Heart J Open*. [Epidemiology / Natural History]
Chen H (2025). [PMID: 41063983](https://pubmed.ncbi.nlm.nih.gov/41063983/). *Front Immunol*. [Basic Science / Preclinical]
Lin K (2025). [PMID: 40682481](https://pubmed.ncbi.nlm.nih.gov/40682481/). *J Cell Mol Med*. [Basic Science / Preclinical]
Gunnersen S (2025). [PMID: 41223601](https://pubmed.ncbi.nlm.nih.gov/41223601/). *Atherosclerosis*. [Basic Science / Preclinical]
Buianova AA (2025). [PMID: 41479884](https://pubmed.ncbi.nlm.nih.gov/41479884/). *Front Immunol*. [Case Report / Case Series]
Sherwani MA (2025). [PMID: 41096629](https://pubmed.ncbi.nlm.nih.gov/41096629/). *Int J Mol Sci*. [Case Report / Case Series]
Jurczuk A (2025). [PMID: 41369391](https://pubmed.ncbi.nlm.nih.gov/41369391/). *Cells*. [Review / Meta-Analysis]